Cargando…

Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells

Standard treatment for primary prostate cancer includes systemic exposure to chemotherapeutic drugs that target androgen receptor or antihormone therapy (chemical castration); however, drug-resistant cancer cells generally emerge during treatment, limiting the continued use of systemic chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yayun, Mafuvadze, Benford, Aebi, Johannes D, Hyder, Salman M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892832/ https://www.ncbi.nlm.nih.gov/pubmed/27313468 http://dx.doi.org/10.2147/OTT.S105725

Ejemplares similares

Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
por: Liang, Yayun, et al.
Publicado: (2017)

Cholesterol biosynthesis inhibitor RO 48-8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway
por: Ding, Zhen, et al.
Publicado: (2021)

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
por: Liang, Yayun, et al.
Publicado: (2018)

Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro
por: Goyette, Sandy, et al.
Publicado: (2017)

Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts
por: Cook, Matthew T., et al.
Publicado: (2015)

Dental caries and oral health practice among 12 year old school children from low socio-economic status background in Zimbabwe
por: Mafuvadze, Brighton Tasara, et al.
Publicado: (2013)

The impact of traditional and religious practices on the spread of Ebola in West Africa: time for a strategic shift
por: Manguvo, Angellar, et al.
Publicado: (2015)

Breast cancer knowledge and awareness among university students in Angola
por: Sambanje, Martha Nyanungo, et al.
Publicado: (2012)

TGF-β Negatively Regulates CXCL1 Chemokine Expression in Mammary Fibroblasts through Enhancement of Smad2/3 and Suppression of HGF/c-Met Signaling Mechanisms
por: Fang, Wei Bin, et al.
Publicado: (2015)

Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones
por: Hu, Jie, et al.
Publicado: (2010)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

THU542 Inhibiting Oxidosqualene Cyclase Suppresses Cancer Stem-like Cells And Growth Of Epithelial Ovarian Cancer Cells In Vitro And In Vivo
por: Liang, Yayun, et al.
Publicado: (2023)

The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012)

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer
por: Fontana, Fabrizio, et al.
Publicado: (2021)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
por: Zhou, Jianfu, et al.
Publicado: (2021)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
por: Stein, Evan A., et al.
Publicado: (2010)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

Hormone levels following surgical and medical castration: defining optimal androgen suppression
por: Schweizer, Michael T, et al.
Publicado: (2018)

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer
por: Han, W, et al.
Publicado: (2018)

The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development
por: CARROLL, CANDACE E., et al.
Publicado: (2012)

Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
por: Cherif, Chaïma, et al.
Publicado: (2021)

SUN-LB055 Targeting Mutant p53 Alone or in Combination with a Phosphatidylserine Specific Antibody Suppresses Growth and Metastasis of Human Breast Cancer: A Strategy Towards Enhancing Personalized Medicine
por: Liang, Yayun, et al.
Publicado: (2019)

From ZeRO to HeRO: Saving lives one HeRO at a time
por: Ratcliff, Dr. Charlotte, et al.
Publicado: (2016)

Castration for Prostatic Hypertrophy
Publicado: (1899)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis
por: Felix-Patrício, Bruno, et al.
Publicado: (2017)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
por: Liu, Yufei, et al.
Publicado: (2020)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
por: Hu, Jason, et al.
Publicado: (2022)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
por: Westin, P., et al.
Publicado: (1995)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
por: Moon, Sue Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lca2i4ua8jeb81m2hmnuu6fa1h